Successful Exit: PerkinElmer Agrees to Acquire SIRION Biotech
SIRION Biotech will continue to grow its position in viral vector technologies for cell and gene therapy as part of PerkinElmer
24-Jun-2021 -
High-Tech Gründerfonds, Creathor Ventures, KfW and Bayern Kapital announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. This news comes after ...
cell therapy
gene therapy
PerkinElmer
+1